MEDP vs RVTY
Medpace vs Revvity — AI-powered side-by-side comparison
| Metric | MEDP | RVTY |
|---|
| AI Score |
65
|
72
|
| Price |
$590.35
|
$114.66
|
| P/E Ratio |
33.97×
|
54.60×
|
| ROE |
98.3%
|
3.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
52.1%
|
| Debt / Equity |
0.28×
|
0.46×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
64.4
|
57.8
|
| Beta |
1.151
|
1.091
|
| Expected Upside |
+5.5%
|
+1.3%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus RVTY.
RVTY leads by 7 points.
RVTY scores 72/100 (Buy) versus MEDP at 65/100 (Buy).
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 33.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.5 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Risk/reward is unfavorable: 27.2% downside vs 1.3% upside.